XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2023
Jan. 31, 2022
Revenue:        
Total revenue $ 486,495 $ 413,081 $ 920,104 $ 791,598
Cost of revenue:        
Total cost of revenue 86,805 79,969 169,300 161,415
Gross profit 399,690 333,112 750,804 630,183
Operating expenses:        
Sales and marketing 229,788 241,726 466,010 491,852
Research and development 142,301 141,870 291,744 286,397
General and administrative 84,109 44,291 130,213 84,319
Total operating expenses 456,198 427,887 887,967 862,568
Loss from operations (56,508) (94,775) (137,163) (232,385)
Other expense, net (10,112) (15,332) (23,528) (293,881)
Loss before provision for income taxes (66,620) (110,107) (160,691) (526,266)
Provision for income taxes 4,170 5,309 9,613 9,356
Net loss $ (70,790) $ (115,416) $ (170,304) $ (535,622)
Net loss per share attributable to Class A common stockholders-basic [1] $ (0.31) $ (0.53) $ (0.74) $ (2.47)
Net loss per share attributable to Class A common stockholders-diluted [1] $ (0.31) $ (0.53) $ (0.74) $ (2.47)
Weighted average shares used in computing net loss per share attributable to Class A common stockholders-basic [1] 231,924 218,808 230,229 217,153
Weighted average shares used in computing net loss per share attributable to Class A common stockholders-diluted [1] 231,924 218,808 230,229 217,153
Product        
Revenue:        
Total revenue $ 250,538 $ 209,151 $ 459,112 $ 389,256
Cost of revenue:        
Total cost of revenue 15,506 15,096 28,022 29,317
Support, Entitlements and Other Services        
Revenue:        
Total revenue 235,957 203,930 460,992 402,342
Cost of revenue:        
Total cost of revenue $ 71,299 $ 64,873 $ 141,278 $ 132,098
[1] Effective January 3, 2022, all of the then outstanding shares of Nutanix, Inc. Class B common stock were automatically converted into the same number of shares of Nutanix, Inc. Class A common stock. See Note 9 for further details.